Stocks and Investing Stocks and Investing
Fri, January 20, 2023
Thu, January 19, 2023

Colin Rusch Maintained (AMED) at Buy with Decreased Target to $125 on, Jan 19th, 2023


Published on 2024-10-28 01:00:05 - WOPRAI, Colin Rusch
  Print publication without navigation


Colin Rusch of Oppenheimer, Maintained "Amedisys, Inc." (AMED) at Buy with Decreased Target from $145 to $125 on, Jan 19th, 2023.

Colin has made no other calls on AMED in the last 4 months.



There are 9 other peers that have a rating on AMED. Out of the 9 peers that are also analyzing AMED, 3 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whit Mayo of "SVB Leerink" Maintained at Hold with Decreased Target to $85 on, Thursday, January 5th, 2023
  • Scott Fidel of "Stephens & Co." Maintained at Hold with Decreased Target to $106 on, Friday, November 11th, 2022
  • John Ransom of "Raymond James" Downgraded from Buy to Hold on, Thursday, October 27th, 2022


These are the ratings of the 6 analyists that currently disagree with Colin


  • Frank Morgan of "RBC Capital" Maintained at Buy with Decreased Target to $139 on, Monday, October 31st, 2022
  • David Macdonald of "Truist Securities" Maintained at Strong Buy with Decreased Target to $130 on, Friday, October 28th, 2022
  • Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $145 on, Friday, October 28th, 2022
  • Sarah James of "Barclays" Maintained at Buy with Decreased Target to $126 on, Friday, October 28th, 2022
  • Justin Bowers of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $165 on, Monday, October 24th, 2022
  • Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $135 on, Monday, October 3rd, 2022

Contributing Sources